A SUPER-powered WP Engine Atlas Test Site

Joe&#039;s Atlas Experimentation Site

<a href="https://www.everythingals.org/">EverythingALS</a> has introduced a platform aimed at advancing <a href="https://alsnewstoday.com/what-is-als/">amyotrophic lateral sclerosis</a> (ALS) research using artificial intelligence (AI) and machine learning — with the ultimate goal of eradicating the disease and restoring lost motor function to those with ALS and other neurodegenerative disorders.
The collaborative and technology-enabled platform, dubbed the <a href="https://v2030.org/">Vision 2030 AI Hub</a>, will be led by Indu Navar, EverythingALS&#8217; founder and CEO, and Bill Nuti, the nonprofit’s chairman.
“We are unified in our conviction that AI is not just a technological breakthrough — it is the beacon of hope for medical research and will profoundly redefine the future of healthcare and medicine,” Navar said.
In launching Vision 2030, EverythingALS made financial gifts to the Massachusetts Institute of Technology and Massachusetts General Hospital, with the nonprofit stating in a <a href="https://www.globenewswire.com/news-release/2024/03/12/2844699/0/en/EverythingALS-Launches-the-Vision-2030-AI-Hub-Charting-the-Path-to-an-ALS-Cure-and-Advancing-Neurodegenerative-Disease-Research.html">press release</a> that these institutions are &#8220;driving innovative, ground-breaking work in this field.”
The AI hub will seek to unite investigators through a comprehensive data, technology, and industry-partner supply chain. Together, according to EverythingALS, these partners will be able to quickly translate basic science discoveries in regeneration and repair into life-changing therapies.
[recommended-reading id=85557]
<h3>Everything ALS will use AI platform to seek a cure for ALS</h3>
In addition to investigators, the platform will include biotech and pharmaceutical companies, hospital clinics, academia, government agencies, and foundations seeking an ALS cure.
The AI platform is part of the organization’s Vision 2030 initiative, which seeks to address historical impediments to treatment development, such as insufficient funding and a lack of technology infrastructure, as well as a dearth of data science expertise.
“ALS research, in both the private and public sectors, is severely impeded by slow and cumbersome funding processes, and the limited availability of grants due to ALS’s lower prevalence,” Nuti said, adding that “this scarcity of resources [forces] researchers to spend considerable time seeking financial support, often through charitable means.&#8221;
EverythingALS is looking to change that paradigm.
&#8220;This stark reality underscores a pressing need for a radical change in approach to ensure that no promising research is left on the sidelines, and we accelerate the process of developing a cure. Vision 2030 is the right operating model to address these challenges,” Nuti said.
According to Navar, the platform &#8220;will strategically harness the power of advanced technology and collective clinical know-how to foment meaningful progress.&#8221;
“Along with a solid operational plan, we have reached a pivotal moment in history, where quantum advancements in science and technology can be applied to the effort and transcend human limitations,” Navar said.
Key hub features include a unique network — an ecosystem that harnesses cutting-edge innovation in AI, generative AI, and large language models. The platform also will have a “laser focus” on research targeting repair and regeneration and will establish an extensive “data lake” of such research for global availability to scientists, the release states.
It also will feature a so-called frictionless operating framework, in that it will provide research tools and resources to eliminate the burden of grant application and funding. Further, its partners are expected to work together to ultimately streamline the therapy development process.
[quote=&#8221;center&#8221;]Along with a solid operational plan, we have reached a pivotal moment in history, where quantum advancements in science and technology can be applied to the effort and transcend human limitations.[/quote]
Ernest Fraenkel, PhD, an MIT professor of biological engineering, noted that “EverythingALS has a singular yet powerful mission — to dissect and understand the various subtypes of ALS and uncover their causes.”
The chair of the Vision 2030 AI Hub steering committee, Merit Cudkowicz, MD — also the director of the Sean M. Healey &amp; AMG Center for ALS at Mass General — says &#8220;this is the nexus where our collective strides become a giant leap for mankind.&#8221;
“Across the annals of medical research, progress often emerges in fragments, illuminating the path piece by piece,” Cudkowicz said.
“Yet, it is not until these fragments unite that we witness the dawn of a transformation. The Vision 2030 AI Hub epitomizes this momentous convergence — where the cumulative advances in ALS research and technology coalesce, heralding a new epoch of hope and discovery,” Cudkowicz said.
To encourage financial support, Vision 2030 AI Hub’s operating model will emphasize the urgency of conducting research into cures for ALS and other neurodegenerative disorders, rather than treatments that manage symptoms.
For more information on the AI platform, send an email to info@everythingALS.org.

EverythingALS launches AI platform to accelerate ALS research

With an aim to share expertise and diminish duplicative research and care efforts in <a href="https://alsnewstoday.com/what-is-als/">amyotrophic lateral sclerosis</a> (ALS), two nonprofits — <a href="https://www.everythingals.org/">EverythingALS</a> and <a href="https://www.wewillcureals.com/">CureALS</a> — are combining operations on the EverythingALS platform, with an emphasis on research.
The new single nonprofit also will tackle efforts to find a cure for the related neurodegenerative condition frontotemporal dementia (FTD).
“We firmly believe that the proliferation of non-profit organizations in this field leads to duplication of efforts, wasting precious time, money, and most importantly, lives,” Bill Nuti, CureALS’ founder and CEO and now chairman of the board of directors for Everything ALS, said in a <a href="https://www.businesswire.com/news/home/20230711610576/en/EverythingALS-and-CureALS-Join-Forces-to-Discover-a-Cure-for-ALS">joint press release</a>.
If everyone knew what everyone knows, we would be so much further along in our pursuit of a cure,” Nuti said.
The merger leverages the organizations&#8217; disease knowledge, resources, and strategic plans, and fortifies their commitment to patient care, research, public and private partnerships, data innovation, and the use of artificial intelligence (AI). The goal is to propel innovative, citizen-driven ALS research, the new partners said.
[recommended-reading id=83660]
<h3>More research needed to advance &#8216;archaic&#8217; treatment</h3>
Going into the merger, EverythingALS was awaiting the results of several ongoing ALS digital biomarker observational studies — including the <a href="https://alsnewstoday.com/news/speech-study-artificial-intelligence-ai-technology-als-biomarkers/">Speech study</a> and the <a href="https://alsnewstoday.com/news/trial-planned-digital-home-monitoring-als-progression/">Radcliff study</a>  — with support from open data sharing. Those findings are expected in six to 12 months.
“Today, ALS is diagnosed at the equivalent state of Stage 4 cancer, while our treatment measurements remain archaic,&#8221; said Indu Navar, EverythingALS’s founder and CEO.
&#8220;We must break down silos and foster collaboration to accelerate progress,” Navar added.
AI already has played a prominent role in each organization&#8217;s efforts in ALS and FTD —  and that will continue.
“Artificial intelligence is the most consequential technology development in history and is central to both organizations,” Nuti said, adding that “it will significantly contribute to our research and advancements in the field.”
Unified operations on the EverythingALS platform will be guided by the following priorities:
<ul>
<li>To fund and support curative research with an emphasis on regeneration and repair of neurons and axons, or nerve fibers, using AI and technology innovations.</li>
<li>To drive digital biomarker identification and innovation to improve early diagnoses, treatments, and data feedback for curative investigations.</li>
<li>To enhance data sourcing, acquisition, and innovation to improve analysis and technology utilization.</li>
<li>To educate, empower, and support ALS patients so they understand their treatment options and make informed decisions.</li>
</ul>
“These priorities encompass the important strategic themes for the combined entity,” Nuti said.
“They reflect our commitment to advancing research, improving diagnosis and therapies, leveraging data for analysis and technology integration, and ensuring comprehensive support for people living with ALS and FTD,” he said.
Each organization has actively been building an expansive global ecosystem of partners that include industry, academia, and government. Both also have worked toward more research sharing, which fosters collaboration, knowledge sharing, and resource pooling to maximize the impact of ALS research and investigations.
“CureALS is EverythingALS&#8217;s vehicle to focus on research to discover a cure, without overlap in approach,” Navar said, adding, “Our synergy is evident, and our powerful strategic alignment will propel us forward in our mission.”
[quote=&#8221;center&#8221;]CureALS is EverythingALS&#8217;s vehicle to focus on research to discover a cure, without overlap in approach.[/quote]
Since 2020, EverythingALS has sought to advance research, foster innovation, and support patients and families. The pioneering CureALS has worked to fund groundbreaking research and empower those with ALS.
“By combining our resources, expertise, and strategic plans, EverythingALS is poised to drive revolutionary advancements and positively impact the lives of patients and their families,” the release stated.

Tag: EverythingALS

EverythingALS launches AI platform to accelerate ALS research

Merging as EverythingALS, 2 nonprofits seek to better treatment